Enters Into An Agreement To Amend Worldwide Collaboration And License For Four Compounds Including Ulotaront With Otsuka
15/03/2024 06:32
March 15 (Reuters) - Sumitomo Pharma Co Ltd 4506.T :
* ENTERS INTO AN AGREEMENT TO AMEND WORLDWIDE COLLABORATION
AND
LICENSE FOR FOUR COMPOUNDS INCLUDING ULOTARONT WITH OTSUKA
Source text for Eikon: ID:nTSoo87542
Further company coverage: 4506.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug